A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Clinical trial NCT02631070 · COMPLETED

Trial details

NCT number: NCT02631070
Sponsor: Celgene
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Myelodysplastic Syndromes

Start date: 2016-02-09
Primary completion: 2019-06-18
Enrollment: 229

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.